Milgamma N (Thiamine Hydrochloride, Cyanocobalamin, Pyridoxine Hydrochloride, Lidocaine Hydrochloride)

Milgamma N is indicated for conditions related to vitamin B deficiency and neuropathic pain.

• Vitamin B1, B6 and B12 deficiency: restores deficient vitamin levels and supports normal metabolic functions.
• Peripheral neuropathy: alleviates nerve dysfunction symptoms and reduces pain associated with neuropathic damage.
• Neuralgia: provides local analgesia to relieve sharp, shooting pain in affected nerves.

• Milgamma N delivers thiamine, cyanocobalamin and pyridoxine, which act as essential cofactors in carbohydrate metabolism, DNA synthesis and amino‑acid neurotransmitter pathways, respectively. Lidocaine hydrochloride blocks voltage‑gated sodium channels in neuronal membranes, producing reversible local anaesthesia and analgesia. The combined effect corrects vitamin B deficiencies while simultaneously dampening ectopic nerve firing, contributing to pain relief in neuropathic conditions.

Adverse reactions to Milgamma N may vary in frequency and severity.

Common Side Effects

• Injection site pain: mild discomfort at the intramuscular site.
• Redness or swelling: localized erythema or edema.
• Nausea: transient feeling of queasiness.
• Dizziness: brief light‑headedness after administration.
• Headache: mild to moderate headache.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, swelling, or anaphylaxis.
• Severe hypotension: marked drop in blood pressure requiring monitoring.
• Cardiac arrhythmia: irregular heartbeat linked to lidocaine toxicity.
• Stevens‑Johnson syndrome: rare severe skin reaction.
• Neurological disturbances: seizures or convulsions in extreme cases.

Before prescribing Milgamma N, clinicians should consider several safety precautions.

• Assess vitamin B status: confirm deficiency before initiating therapy.
• Monitor for hypersensitivity: observe for signs of allergic reaction during and after injection.
• Cardiac caution: use with care in patients with conduction disorders or heart failure due to lidocaine effects.
• Drug interaction review: evaluate concurrent medications that may potentiate lidocaine toxicity.
• Pregnancy and lactation: safety not established; weigh potential benefits against unknown risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milgamma N may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid)

• Other local anesthetics: concurrent use can increase systemic lidocaine toxicity.
• Class I antiarrhythmic agents (e.g., quinidine, procainamide): additive effects on cardiac conduction may cause arrhythmias.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise lidocaine plasma concentrations.

Moderate Interactions (Monitor Closely)

• Alcohol consumption: may enhance lidocaine‑induced hypotension and dizziness.
• High‑dose vitamin B supplements: risk of excess B‑vitamin levels, especially B6 neuropathy.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce lidocaine effectiveness.